Zoeticx, a developer of medical software that bridges the gap between medical data and patient care, today announced a crowd funding campaign for TruRecord, the first subscriber-based, medical prescribing software to leverage advanced DNA testing technology for optimal drug analysis and prevention of adverse drug reactions.
The company is raising funds for a fall launch of TruRecord on medical crowd funding site Medstartr.
TruRecord is designed to foster better patient outcomes by helping to prevent the 100,000 deaths yearly from drugs that are prescribed properly and 80,000 deaths from those which are not, resulting in 289 billion spent annually on malpractice payouts.
Through the visualization of drug-to-drug interactions, drug-to-allergy interactions, and drug to DNA metabolization, medical professionals can now create what-if scenarios for drug issues, enabling providers to personalize prescriptions. This capability breaks through providers’ drug analysis limitations and the burdensome task of scanning and searching text and tables to identify adverse reaction data which is often complex.
TruRecord client interfaces are supported on mobile and web interfaces, providing precise, personalized medication prescription. TruRecord accesses patient medical record via an on-demand, real time access from EHR / EMR systems. Without data duplication, TruRecord complies with all required secure patient privacy protection outlined by HIPAA.
“We built Zoeticx to help medical systems address interoperability, lower accidental deaths and bridge the gap between medical data and better patient outcomes,” said Thanh Tran, CEO, Zoeticx. “Today our goal is the same, but a shift toward an additional focus—adverse drug reactions. We are ushering in an era where we can leverage the fruits of DNA research to bring more precise and accurate prescriptions to those who rely on them. TruRecord takes the guess work out of drug interactions and patients by delivering security, peace of mind and accuracy.”
